Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Aug;161(2):223-32.
doi: 10.1111/j.1365-2249.2010.04197.x. Epub 2010 May 31.

Immunotherapy prospects for acute myeloid leukaemia

A J Barrett  1 , K Le Blanc
Affiliations
Review

Immunotherapy prospects for acute myeloid leukaemia

A J Barrett et al. Clin Exp Immunol. 2010 Aug.

Abstract

While chemotherapy is successful at inducing remission of acute myeloid leukaemia (AML), the disease has a high probability of relapse. Strategies to prevent relapse involve consolidation chemotherapy, stem cell transplantation and immunotherapy. Evidence for immunosurveillance of AML and susceptibility of leukaemia cells to both T cell and natural killer (NK) cell attack and justifies the application of immune strategies to control residual AML persisting after remission induction. Immune therapy for AML includes allogeneic stem cell transplantation, adoptive transfer of allogeneic or autologous T cells or NK cells, vaccination with leukaemia cells, dendritic cells, cell lysates, peptides and DNA vaccines and treatment with cytokines, antibodies and immunomodulatory agents. Here we describe what is known about the immunological features of AML at presentation and in remission, the current status of immunotherapy and strategies combining treatment approaches with a view to achieving leukaemia cure.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Interactions between acute myeloid leukaemia (AML) cells with the immune milieu.
Fig. 2
Fig. 2
Immunotherapeutic strategies for acute myeloid leukaemia (AML).
See this image and copyright information in PMC

References

    1. Gale RP, Foon KA. Therapy of acute myelogenous leukemia. Semin Hematol. 1987;24:40–54. - PubMed
    1. Powles RL, Russell J, Lister TA, et al. Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient. Br J Cancer. 1977;35:265–72. - PMC - PubMed
    1. Barrett AJ. Understanding and harnessing the graft-versus-leukaemia effect. Br J Haematol. 2008;142:877–88. - PubMed
    1. Whiteway A, Corbett T, Anderson R, Macdonald I, Prentice HG. Expression of co-stimulatory molecules on acute myeloid leukaemia blasts may effect duration of first remission. Br J Haematol. 2003;120:442–51. - PubMed
    1. Berke G. The CTL's kiss of death. Cell. 1995;81:9–12. - PubMed